122 related articles for article (PubMed ID: 31660743)
1. Multiple Synthetic Routes to the Mini-Protein Omomyc and Coiled-Coil Domain Truncations.
Brown ZZ; Mapelli C; Farasat I; Shoultz AV; Johnson SA; Orvieto F; Santoprete A; Bianchi E; McCracken AB; Chen K; Zhu X; Demma MJ; Lacey BM; Canada KA; Garbaccio RM; O'Neil J; Walji A
J Org Chem; 2020 Feb; 85(3):1466-1475. PubMed ID: 31660743
[TBL] [Abstract][Full Text] [Related]
2. Omomyc Reveals New Mechanisms To Inhibit the MYC Oncogene.
Demma MJ; Mapelli C; Sun A; Bodea S; Ruprecht B; Javaid S; Wiswell D; Muise E; Chen S; Zelina J; Orvieto F; Santoprete A; Altezza S; Tucci F; Escandon E; Hall B; Ray K; Walji A; O'Neil J
Mol Cell Biol; 2019 Nov; 39(22):. PubMed ID: 31501275
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of Myc transcriptional activity by a mini-protein based upon Mxd1.
Demma MJ; Hohn MJ; Sun A; Mapelli C; Hall B; Walji A; O'Neil J
FEBS Lett; 2020 May; 594(10):1467-1476. PubMed ID: 32053209
[TBL] [Abstract][Full Text] [Related]
4. Intrinsic cell-penetrating activity propels Omomyc from proof of concept to viable anti-MYC therapy.
Beaulieu ME; Jauset T; Massó-Vallés D; Martínez-Martín S; Rahl P; Maltais L; Zacarias-Fluck MF; Casacuberta-Serra S; Serrano Del Pozo E; Fiore C; Foradada L; Cano VC; Sánchez-Hervás M; Guenther M; Romero Sanz E; Oteo M; Tremblay C; Martín G; Letourneau D; Montagne M; Morcillo Alonso MÁ; Whitfield JR; Lavigne P; Soucek L
Sci Transl Med; 2019 Mar; 11(484):. PubMed ID: 30894502
[TBL] [Abstract][Full Text] [Related]
5. Comparative analysis of compound NSC13728 as Omomyc homodimer stabilizer by molecular dynamics simulation and MM/GBSA free energy calculation.
Gao J; Wang Y; Li K; Zhang J; Geng X
J Mol Model; 2022 Mar; 28(4):92. PubMed ID: 35294626
[TBL] [Abstract][Full Text] [Related]
6. Computational insights into the differentiated binding affinities of Myc, Max, and Omomyc dimers to the E-boxes of DNA.
Dai Y; Zhang J; Wang Y; Liu L; Gao J
J Mol Model; 2022 Sep; 28(10):329. PubMed ID: 36149511
[TBL] [Abstract][Full Text] [Related]
7. Omomyc, a potential Myc dominant negative, enhances Myc-induced apoptosis.
Soucek L; Jucker R; Panacchia L; Ricordy R; Tatò F; Nasi S
Cancer Res; 2002 Jun; 62(12):3507-10. PubMed ID: 12067996
[TBL] [Abstract][Full Text] [Related]
8. Myc and Omomyc functionally associate with the Protein Arginine Methyltransferase 5 (PRMT5) in glioblastoma cells.
Mongiardi MP; Savino M; Bartoli L; Beji S; Nanni S; Scagnoli F; Falchetti ML; Favia A; Farsetti A; Levi A; Nasi S; Illi B
Sci Rep; 2015 Nov; 5():15494. PubMed ID: 26563484
[TBL] [Abstract][Full Text] [Related]
9. The action mechanism of the Myc inhibitor termed Omomyc may give clues on how to target Myc for cancer therapy.
Savino M; Annibali D; Carucci N; Favuzzi E; Cole MD; Evan GI; Soucek L; Nasi S
PLoS One; 2011; 6(7):e22284. PubMed ID: 21811581
[TBL] [Abstract][Full Text] [Related]
10. Design and properties of a Myc derivative that efficiently homodimerizes.
Soucek L; Helmer-Citterich M; Sacco A; Jucker R; Cesareni G; Nasi S
Oncogene; 1998 Nov; 17(19):2463-72. PubMed ID: 9824157
[TBL] [Abstract][Full Text] [Related]
11. OmoMYC blunts promoter invasion by oncogenic MYC to inhibit gene expression characteristic of MYC-dependent tumors.
Jung LA; Gebhardt A; Koelmel W; Ade CP; Walz S; Kuper J; von Eyss B; Letschert S; Redel C; d'Artista L; Biankin A; Zender L; Sauer M; Wolf E; Evan G; Kisker C; Eilers M
Oncogene; 2017 Apr; 36(14):1911-1924. PubMed ID: 27748763
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of cMYC-MAX transcription factors hetero-dimerization with structurally engineered omoMYC to downregulate oncogenic pathways in renal carcinoma.
Li W; Bano F; Khan A; Wei DQ; Alshammari A; Xu B; Wang Y
Comput Biol Med; 2023 Sep; 164():107257. PubMed ID: 37527610
[TBL] [Abstract][Full Text] [Related]
13. Preferential heterodimeric parallel coiled-coil formation by synthetic Max and c-Myc leucine zippers: a description of putative electrostatic interactions responsible for the specificity of heterodimerization.
Lavigne P; Kondejewski LH; Houston ME; Sönnichsen FD; Lix B; Skyes BD; Hodges RS; Kay CM
J Mol Biol; 1995 Dec; 254(3):505-20. PubMed ID: 7490766
[TBL] [Abstract][Full Text] [Related]
14. Omomyc expression in skin prevents Myc-induced papillomatosis.
Soucek L; Nasi S; Evan GI
Cell Death Differ; 2004 Sep; 11(9):1038-45. PubMed ID: 15143346
[TBL] [Abstract][Full Text] [Related]
15. A chemical approach for the synthesis of the DNA-binding domain of the oncoprotein MYC.
Calo-Lapido R; Penas C; Jiménez-Balsa A; Vázquez ME; Mascareñas JL
Org Biomol Chem; 2019 Jul; 17(28):6748-6752. PubMed ID: 31166361
[TBL] [Abstract][Full Text] [Related]
16. Blocking Myc to Treat Cancer: Reflecting on Two Decades of Omomyc.
Massó-Vallés D; Soucek L
Cells; 2020 Apr; 9(4):. PubMed ID: 32260326
[TBL] [Abstract][Full Text] [Related]
17. Resetting cancer stem cell regulatory nodes upon MYC inhibition.
Galardi S; Savino M; Scagnoli F; Pellegatta S; Pisati F; Zambelli F; Illi B; Annibali D; Beji S; Orecchini E; Alberelli MA; Apicella C; Fontanella RA; Michienzi A; Finocchiaro G; Farace MG; Pavesi G; Ciafrè SA; Nasi S
EMBO Rep; 2016 Dec; 17(12):1872-1889. PubMed ID: 27852622
[TBL] [Abstract][Full Text] [Related]
18. MYC as a target for cancer treatment.
Duffy MJ; O'Grady S; Tang M; Crown J
Cancer Treat Rev; 2021 Mar; 94():102154. PubMed ID: 33524794
[TBL] [Abstract][Full Text] [Related]
19. Targeting the c-Myc coiled coil with interfering peptides.
Jouaux EM; Schmidtkunz K; Müller KM; Arndt KM
J Pept Sci; 2008 Sep; 14(9):1022-31. PubMed ID: 18465834
[TBL] [Abstract][Full Text] [Related]
20. Dimerization of CtIP, a BRCA1- and CtBP-interacting protein, is mediated by an N-terminal coiled-coil motif.
Dubin MJ; Stokes PH; Sum EY; Williams RS; Valova VA; Robinson PJ; Lindeman GJ; Glover JN; Visvader JE; Matthews JM
J Biol Chem; 2004 Jun; 279(26):26932-8. PubMed ID: 15084581
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
